KTTA - CONSENSUS CO - Pasithea Therapeutics

The Pasithea Therapeutics (KTTA) market valuation chart on the GURU.Markets platform shows a value of 3.01, while the business is building a comprehensive psychological support environment by combining specialized centers with the development of new drugs. The strategy relies on multi-year patent protection for formulas treating severe pathologies, and human capital is provided by a strong team of biochemists dedicated to long-term scientific objectives.

This indicator represents the aggregated business value, reflecting the dynamic restructuring of analysts' valuation models based on macroeconomics and cash flows. By assessing asset resilience through the consolidated target forecasts of investment banks, investors can track how contract line utilization and the calibration of sterile equipment at Pasithea Therapeutics (KTTA) impact the fundamental attractiveness of the company's shares.